India, May 11 -- Daiichi Sankyo Company Limited (DSKYF) on Monday unveiled its new five-year business plan for fiscal 2026-2030, targeting oncology revenue of more than 2.3 trillion yen by 2030 and aiming to become a global top-five oncology company by 2035.
The company expects revenue to exceed 3 trillion yen by fiscal 2030, up from 2.1 trillion yen reported for fiscal 2025, driven by expansion of its oncology portfolio, particularly its DXd antibody drug conjugate platform.
Operating profit is forecast to exceed 600 billion yen by fiscal 2030, with earnings per share expected to surpass 260 yen. The company also targets an adjusted dividend on equity of 10% or higher annually and progressive dividends. Operating profit is projected to r...